决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:An Optimized Method for Single Cell Cloning of Human CAR-T Cells Based on FBS-Coated Plates.
这种新方法高效、经济且可扩展,可用于分离特定的均一T细胞并促进其克隆性增殖和扩增。此外,该方法改善了T细胞黏附、增殖和功能有效性,为推进针对实体瘤的CAR-T细胞疗法提供了潜在基础。未来研究应集中于优化培养条件,并在临床前动物模型中测试该方法,以确保其临床适用性和疗效。
基于T细胞的免疫疗法,尤其是嵌合抗原受体(CAR)-T细胞,已成为治疗血液系统恶性肿瘤的合适方法,目前正在实体瘤的临床试验中进行研究。尽管CAR-T细胞生产工艺有了显著改进,但CAR工程化T细胞的分离和扩增仍然面临重大挑战。本研究的目的是提供一种简单且经济有效的方法,用于人CAR-T细胞的分离和扩增。这一新概念应用包被胎牛血清(FBS)的培养板,并专注于增强活力和功能,以改善悬浮T细胞的贴壁。
本研究评估了一种二维(2D)培养技术,用于分离靶向前列腺特异性膜抗原(PSMA)的 CAR-T 细胞,该技术利用预先涂有 0.2% 戊二醛和 FBS 的基质。用编码抗 PSMA CAR 构建体的慢病毒载体转导 Jurkat 细胞。使用 FBS 包被和商业化 Matrigel 包被的基质进行单细胞分离和克隆扩增。在克隆和扩增后,进行功能测试以评估 CAR-T 细胞的活化和增殖以及 IFN-释放试验。
转染效率显著提高,88.4%的Lenti-X 293T细胞表现出绿色荧光蛋白(GFP)表达。在Jurkat细胞中,57.1%在转导后表现出GFP表达,其中34.1%表现出抗PSMA CAR的表面表达。在FBS包被的基质上进行克隆扩增被证明是有效的,产生了92.1%GFP阳性的分离细胞。功能实验表明,与DU 145和mock细胞共培养相比,与LNCaP细胞共培养的CAR-T细胞表现出显著增强的增殖、活化(由CD69和CD25表达指示)和细胞因子释放实验(IFN-)。
PURPOSE: T cell-based immunotherapy, especially chimeric antigen receptor (CAR)-T cells, has emerged as an appropriate approach for treating hematologic malignancies and is currently under investigation in clinical trials for solid tumors. Despite significant improvements in CAR-T cell production processes, the isolation and expansion of CAR-engineered T cells continue to pose significant challenges. The aim of this research is to provide a simple and cost-effective method for the isolation and expansion of human CAR-T cells. This novel concept applies coated fetal bovine serum (FBS) culture plates and focuses on enhancing viability and functionality to improve the adherence of suspended T cells. METHODS: This study evaluated a two-dimensional (2D) culture technique for isolating the CAR-T cells that target prostate-specific membrane antigen (PSMA) utilizing matrices pre-coated with 0.2% glutaraldehyde and FBS. Jurkat cells were transduced with a lentiviral vector encoding the anti-PSMA CAR construct. FBS-coated and commercialized Matrigel-coated matrices were used for single-cell isolation and clonal expansion. Functional tests were conducted to assess the activation and proliferation of CAR-T cells and the IFN- release assay subsequent to cloning and expansion. RESULTS: Transfection efficiency markedly improved, with 88.4% of Lenti-X 293T cells demonstrating green fluorescent protein (GFP) expression. Among the Jurkat cells, 57.1% showed GFP expression post-transduction, of which 34.1% showed surface expression of anti-PSMA CAR. Clonal expansion on the FBS-coated matrix proved effective, yielding 92.1% GFP-positive isolated cells. Functional assays demonstrated that CAR-T cells co-cultured with LNCaP cells exhibited significantly enhanced proliferation, activation (as indicated by CD69 and CD25 expression), and cytokine release assay (IFN- ) compared with those co-cultured with DU 145 and mock cells. CONCLUSION: This new approach is efficient, economical, and scalable for isolating specific homogenous T cells and promoting their clonal proliferation and expansion. Furthermore, this method improves T cell adherence, proliferation, and functional effectiveness, offering a potential foundation for advancing CAR-T cell therapies aimed at solid tumors. Future research should concentrate on optimizing culture conditions and testing this method in preclinical animal models to ensure its clinical applicability and efficacy.
MEMBER ACCOUNT
登录成功会直接打开下一页。